Interview with Richard Blackburn, Managing Director, Pfizer UK
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Address: No. 2, 32 Caxton Road,
Shepherd’s Bush, London W12 8AJ,United Kingdom
Tel: +44 (0)20 ‐ 7229 4552
Web: http://www.dwlanguages.com/page.asp?node=2
DWL is a specialist translation service provider for the pharmaceutical industry providing Medical Translation into all European Union (EU) and European Economic Area (EEA) languages and many others – mainly “from” and “into” English
Established in 1962, our business has grown through dedication and commitment to quality and service. This is acknowledged by our many long-standing clients and is perhaps most clearly demonstrated by their recommendation of DWL to others.
By recognising the specific needs of this market, DWL delivers a quality Medical Translation Service due to its expertise in selecting the most suitable linguists in combination with reliable project management and quality control. We understand the need to be flexible and responsive in our service, and that accuracy and thoroughness remain essential – even within the tightest of project timelines.
DW Languages provides translation solutions for the following areas:
Medical translation services
Pharmaceutical translation
Regulatory affairs
Clinical trials
Medical research and manufacturing
Legal documentation
Medical publishing and marketing communications
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
